Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Sep;10(9):715-725.
doi: 10.1177/1756283X17721152. Epub 2017 Jul 24.

The place of eluxadoline in the management of irritable bowel syndrome with diarrhea

Sherry Levio  1 , Brooks D Cash  2
Affiliations
Review

The place of eluxadoline in the management of irritable bowel syndrome with diarrhea

Sherry Levio et al. Therap Adv Gastroenterol. 2017 Sep.

Abstract

Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder characterized by abdominal pain associated with defecation with altered stool frequency or stool form. The global prevalence of IBS ranges from 10% to 15% and total healthcare cost attributable to IBS is significant. Among individuals with IBS, the condition has dramatic effects on health-related quality of life, work and school productivity, and activities of daily living. It may be diagnosed with confidence, based on symptom-based diagnostic criteria, exclusion of alarm features and directed diagnostic testing. Management of IBS typically begins with dietary and lifestyle modifications, progressing to over-the-counter therapies, and then to prescription medications, both approved and nonapproved for IBS. This narrative summarizes the efficacy and safety of three US Food and Drug Administration (FDA)-approved prescription therapies for IBS with diarrhea (IBS-D), with a focus on the most recently marketed agent, eluxadoline, and its role in the treatment IBS-D.

Keywords: alosetron; diarrhea; eluxadoline; irritable bowel syndrome; opioid modulator; rifaximin.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: BDC has served as a consultant and speaker for Allergan, PLC, Prometheus Laboratories, and Salix Pharmaceuticals.

Figures

Figure 1.
Figure 1.
Mechanism of action of Eluxadoline ©Allergan, 2015. Used with permission from Allergan.
See this image and copyright information in PMC

References

    1. Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA 2015; 313: 949–958. - PubMed
    1. Cash BD, Brian LE, Tharaknath R, et al. Rifaximin and eluxadoline-newly approved treatments for diarrhea-predominant irritable bowel syndrome: What is their role in clinical practice alongside alosetron? Expert Opin Pharmacotherapy 2015; 17: 311–322. - PubMed
    1. Saito YA, Schoenfeld P, Locke GR., III The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol 2002; 97: 1910–1915. - PubMed
    1. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012; 10: 712–721. - PubMed
    1. Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol 2014; 6: 71–80. - PMC - PubMed

LinkOut - more resources